The Association of the Immune Response Genes to Human Papillomavirus-Related Cervical Disease in a Brazilian Population

Table 3

Distribution of KIR and HLA ligands in HPV patients and controls.

KIR and HLA ligands	HPV patients		Controls
	𝑛	%	𝑛	%
2DL1-C2	46	67.65	78	67.24
2DL1 without C2	22	32.35	38	32.75
2DL2-C1	28	80.0	43	78.18
2DL2 without C1	7	20.0	12	21.81
2DL3-C1	54	85.71	87	83.65
2DL3 without C1	9	14.29	17	16.34
3DL1-Bw4	44	67.69	73	66.97
3DL1 without Bw4	21	32.31	36	33.02
2DS1-C2	22	73.33	30	60.00
2DS1 without C2	8	26.67	20	40.00
2DS2-C1	30	81.08	45	78.94
2DS2 without C1	7	18.92	12	21.05
3DS1-Bw4	21	67.74	30	62.50
3DS1 without Bw4	10	32.26	18	37.50

Bw4: HLA-A*23, 24, and 32; HLA-B*08, 13, 27, 37, 44, 51, 52, 53, 57, and 58.
Group C1: HLA-C*01, 03, 07, 08, 12, 14, and 16.
Group C2: HLA-C*02, 04, 05, 06, 07, 15, 17, and 18.
Difference was not observed (𝑃≥0.05).